Latest Regulatory News

Australian Rare Earths Limited (ASX: AR3) reports promising extensions of near-surface calcrete-hosted uranium mineralisation at its Overland Uranium Project, reinforcing a dual-asset exploration strategy that combines shallow deposits with deeper in-situ recoverable targets.

Canterbury Resources Limited has completed a $125,000 capital raise through a private placement of 5 million shares, each accompanied by an option exercisable at $0.05 until the end of 2026.

Foresta Group Holdings advances its flagship Kawerau renewable energy project with inclusion in New Zealand’s Fast-Track Approvals Act, a key term sheet with Genesis Energy, and $2 million raised via convertible notes.

Tigers Realm Coal’s planned divestment of its Russian subsidiaries has hit significant regulatory roadblocks, resulting in a reduced sale price, increased exit tax, and suspension from ASX trading.

Hillgrove Resources reported a robust March quarter with a 12% increase in copper production and a 92% rise in mine operating cash flow, underpinned by a successful $18 million capital raise to accelerate growth at Kanmantoo.

Pact Group Holdings has announced its intention to voluntarily delist from the ASX, citing a concentrated shareholder base, low liquidity, and high regulatory costs. Shareholder approval will be sought at an extraordinary general meeting in June 2025.

Fitzroy River Corporation reported steady royalty income for the year ending March 2025, alongside key strategic agreements and a planned capital return, navigating a volatile global energy landscape.

Beach Energy reported steady production and strong financials in Q3 FY25 despite flood disruptions in the Cooper Basin, with key projects advancing and liquidity improving.

Apollo Minerals reports completion of Phase 2 drilling at its Salanie Gold Project with promising high-grade results, alongside strategic funding and ongoing exploration in Gabon, Serbia, and France.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Medical Developments International reported a robust Q3 FY25 with $8.9 million revenue and $1.7 million operating cashflow, driven by strong Penthrox demand and pricing. New distribution agreements in France and Switzerland position the company for further European expansion.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.